1. Home
  2. Labeler Index
  3. Dispensing Solutions, Inc.
  4. 68258-6099
  5. Product Images: Doxazosin Mesylate

Product Images Doxazosin Mesylate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Doxazosin Mesylate NDC 68258-6099 by Dispensing Solutions, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

DOXAZOSIN MESYLATE Molecular Structure - 4abe1804 ae5f 4401 b84c 8ca6a71fbf74 01

DOXAZOSIN MESYLATE Molecular Structure - 4abe1804 ae5f 4401 b84c 8ca6a71fbf74 01

Table 1: SUMMARY OF EFFECTIVENESS DATA IN PLACEBO-CONTROLLED TRIALS - 4abe1804 ae5f 4401 b84c 8ca6a71fbf74 02

Table 1: SUMMARY OF EFFECTIVENESS DATA IN PLACEBO-CONTROLLED TRIALS - 4abe1804 ae5f 4401 b84c 8ca6a71fbf74 02

This text is a summary of effectiveness data in placebo-controlled trials for the treatment of BPH (benign prostatic hyperplasia). It includes three studies where the effectiveness of Doxazosin mesylate was compared to a placebo. The results are presented through mean values of baseline and change in symptom scores and maximum flow rate. The studies were done with a different number of patients and for a different period of time. The text includes some specific details about the measurements used to assess changes in the patient's condition.*

Graph: Mean Change in Total Symptom Score from Baseline - 4abe1804 ae5f 4401 b84c 8ca6a71fbf74 03

Graph: Mean Change in Total Symptom Score from Baseline - 4abe1804 ae5f 4401 b84c 8ca6a71fbf74 03

The text appears to be a graph or chart displaying "Mean Change in Total Symptom Score from Baseline" over a period of "Duration of Treatment (Weeks)". Further information or context is not available.*

Graph: Mean Increase in Maximum Urinary Flow Rate (mL/sec) from Baseline - 4abe1804 ae5f 4401 b84c 8ca6a71fbf74 04

Graph: Mean Increase in Maximum Urinary Flow Rate (mL/sec) from Baseline - 4abe1804 ae5f 4401 b84c 8ca6a71fbf74 04

This is a tabulated data showing the mean increase in maximum urinary flow rate from baseline at different weeks of treatment with Doxazosin. There was no change in flow rate at week 0, but there was a statistically significant increase in flow rate at weeks 2, 4, 6, 8, 10, 12, and 14, compared to baseline and/or placebo (as indicated by the asterisks). The maximum dose of Doxazosin used was 8 mg.*

NDC 68258-6099-XX - NDC 68258 6099 XX PATHEON

NDC 68258-6099-XX - NDC 68258 6099 XX PATHEON

This is a description of Doxazosin Mesylate 1 mg tablets produced by Patheon Puerto Rico, Inc. and includes information such as its product ID, NDC, manufacturer lot number, and pedigree number. The tablets must be kept in tight/light resistant containers and should be taken orally once a day as directed by a physician. It also lists the tablet's warning to keep it out of reach of children and store between 68° - 77° F. Lastly, it displays the drug's packaging information related to its exclusive distribution by DispenseQuick Solitons in Santa Ana, CA.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.